Looking back at the UPC’s ‘successful’ first year

Court seen as “exceeding expectations” | Experts urge caution, emphasising that confident and reliable court judgments are needed | High-stakes patent litigation, especially in pharmaceuticals, remains predominantly within national courts.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Takeda’s China IP head: What pharma is still getting wrong

27 May 2026 China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.

Careers

Boehringer Ingelheim adds ex-Teva executive to patent team

27 May 2026 A senior pharmaceutical lawyer, with experience across private practice and Big Pharma, joins the company after a decade-long tenure at Teva.

Americas

AI, anxiety, and antibodies: The issues dominating life sciences

26 May 2026 Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.

More features

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

UPC judge: ‘Expectations of you as a woman are the challenge’

How should in-house teams adopt AI? ‘Carefully’, says secrets expert

Lupin scores another win in kidney drug dispute

Battle over inhaler shape ends badly for Boehringer

Chinese medtech company fined by UPC over injunction breaches

Looking back at the UPC’s ‘successful’ first year

More on this story

Editor's picks

Editor's picks

More features